Abbott Laboratories $ABT Shares Purchased by Aprio Wealth Management LLC

Aprio Wealth Management LLC boosted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 114.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 14,700 shares of the healthcare product maker’s stock after purchasing an additional 7,861 shares during the period. Aprio Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,842,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in ABT. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares during the last quarter. Capital International Investors raised its stake in Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Abbott Laboratories by 5.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock worth $2,022,080,000 after acquiring an additional 821,325 shares during the period. Invesco Ltd. grew its stake in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Abbott Laboratories by 3.8% in the third quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock valued at $1,804,050,000 after purchasing an additional 499,351 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on ABT. Barclays decreased their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Piper Sandler dropped their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Leerink Partners reduced their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Royal Bank Of Canada lowered their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Finally, Citigroup dropped their price target on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.43.

Insider Activity at Abbott Laboratories

In related news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at $12,053,953.78. The trade was a 0.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares in the company, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,055 shares of company stock valued at $353,097 in the last 90 days. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 0.0%

ABT stock opened at $91.16 on Monday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The company’s 50-day moving average price is $105.96 and its 200 day moving average price is $117.11. Abbott Laboratories has a 52 week low of $90.72 and a 52 week high of $139.06. The company has a market cap of $158.76 billion, a P/E ratio of 25.53, a P/E/G ratio of 1.52 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s payout ratio is currently 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.